Freddy Yip

Cooley advised Otsuka Pharmaceutical, a total healthcare company focused on each individual’s potential to enhance their well-being, on its global strategic collaboration with Harbour BioMed to advance BCMAxCD3 bispecific T-cell engagers for treating autoimmune diseases.

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck KGaA, Darmstadt, Germany for the commercialization in mainland China of SHR7280, an oral small-molecule gonadotropin-releasing hormone receptor antagonist, for indications including medical-assisted reproduction and gynecology.

Cooley advised Puhe BioPharma, a biotechnology company dedicated to the research and development of innovative small-molecule precision therapeutics, on its global license agreement with Bayer for Puhe BioPharma’s oral, small-molecule protein arginine methyltransferase 5 inhibitor that selectively targets metabolic enzyme 5’-deoxy-5’-methylthioadenosine phosphorylase-deleted tumors.

Cooley advised Chimerix (Nasdaq: CMRX), a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, on its definitive agreement to be acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) for $8.55 per share in cash – totaling approximately $935 million.

Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.